TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced an exclusive licensing agreement with Tyson 2.0, the cannabis brand founded by Mike Tyson, to launch its products across Maryland and Pennsylvania. "Cannabis changed my life, and I want to share that with the world,” said Mike Tyson, co-founder of Tyson 2.0. “Partnering with TerrAscend lets us reach more people and deliver products ...

A coalition of 25 state attorneys general on Monday wrote to Shopify , requesting the platform pull its hosting services from websites selling vapes illegally, according to a letter from California's Attorney General's Office. ...

Company’s first dispensary in the Garden State and 8th state where the Company operatesOpened to the public on November 7, 2025Grand opening celebration with exclusive promotions expected November 21, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. BOCA RATON, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced the opening of its B ...

Core Insights - iAnthus Capital Holdings, Inc. has expanded its operations by opening its 24th GrowHealthy dispensary in Fort Myers, Florida, enhancing patient access to premium cannabis products [1][4] - The new dispensary features an expanded lineup of brands, including The Vault, Sunshine State, and MPX, providing patients with greater choice and quality [2][3] - The company emphasizes a flower-first philosophy and community connection, aiming to meet diverse wellness needs through a comprehensive product menu [3][4] Company Overview - iAnthus is a vertically integrated cannabis company focused on building premium brands through cultivation, production, and retail operations across the United States [5] - The company is backed by a leadership team with expertise in cultivation, operations, and capital markets, leveraging acquisition-driven growth for competitive advantage [5] - iAnthus' brand portfolio includes MPX, Anthologie, Black Label, Cheetah, Frūtful, Last Resort, Moodz, Sunshine State, and The Vault [5]

Industry Overview - The cannabis industry is evolving with potential U.S. federal reform and international market expansion, leading to increased global demand for both medical and recreational cannabis [1] - Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes [1] - Navigating this sector requires careful attention to fundamentals, technical analysis, and disciplined risk management [1] Company Highlights IM Cannabis Corp. (IMCC) - IM Cannabis is an international medical cannabis company headquartered in Israel, focusing on the medical market through pharmacy networks and online distribution [3][5] - The company reported a notable increase in annual revenue in 2024, reflecting rising medical demand in Israel and Germany, with modest revenue growth and a small net profit in Q1 2025 [5][11] - IM Cannabis represents a stable, lower-risk option for investors seeking medical cannabis exposure with a strong international foundation [5] Cronos Group Inc. (CRON) - Cronos Group is a Canadian cannabinoid company with a global strategy, focusing on both recreational and medical markets [6][8] - The company reported solid year-over-year revenue growth, supported by strong Canadian adult-use sales and expanding global demand, with improved gross profit margins [8] - Cronos maintains one of the strongest balance sheets in the cannabis industry, providing flexibility for future acquisitions or U.S. market entry [8][11] Aurora Cannabis Inc. (ACB) - Aurora Cannabis is one of Canada's largest cannabis producers, serving both recreational and medical markets with a wide international footprint [9][10] - The company reported significant revenue growth year-over-year, driven by rising medical sales and improved distribution efficiency, with a return to consistent profitability [10][11] - Aurora remains one of the few large-scale producers generating sustainable profits in the global cannabis space, appealing to investors looking for scale and stability [10][11]

Decibel Cannabis Company Conference Call Summary Company Overview - Decibel Cannabis Company is a Canadian cannabis company, established in 2019, and is the sixth largest by market share in Canada [1] - The company operates nationwide with brands including Qwest, Vox, and General Admission, the latter being a top-three brand in Canada [1] - The cannabis industry is experiencing significant growth, projected at a 25% compound annual growth rate (CAGR) through 2033 [1] Industry Insights - The cannabis market is highly fragmented with no single dominant player, allowing for growth opportunities alongside competitors [2] - Canada has contributed to a 54% growth in the global cannabis market through exports [2] - The Canadian market is viewed as mature, growing at approximately 5% annually, while nascent markets in Europe, particularly Germany, are experiencing rapid growth [4][5] International Expansion - Decibel has entered international markets, leveraging learnings from the Canadian market to drive growth [3] - The company expects double-digit growth from international sales, which currently represent 15% of total sales, compared to single-digit growth from domestic sales [7] - International sales increased by 187% quarter-over-quarter [7] - The company is well-positioned with necessary licensing for flower and extract exports, holding one of 13 licenses for flower exports and one of three for extract exports [13] Product Strategy - Decibel focuses on value-added products such as pre-rolls and vapes, which are differentiated from traditional flower products [8] - The company has a broad product array addressing 98% of total sales in the marketplace [9] - International markets are primarily medical, with a focus on flower products, but Decibel plans to introduce extract products as markets mature [9] Financial Performance - The company has maintained profitability and revenue growth, with a target of $25 million EBITDA for 2025 [13] - Year-over-year growth of 7% in the domestic market has been observed, with expectations of continued growth [15] - The company has generated adjusted free cash flow for the past three years and maintains margins close to 50% [16][17] Market Positioning - Decibel's management team has been consistent since inception, contributing to a strong track record of profitability in a challenging sector [6] - The company aims to balance debt and equity, maintaining a comfortable debt-to-EBITDA ratio of approximately two times [18] - The management believes that driving fundamental success through cash flow is key to creating long-term value for shareholders [17] Regulatory Environment - The cannabis industry is highly regulated, treated similarly to pharmaceuticals, which presents both challenges and opportunities for compliance and market entry [13] - Decibel's acquisition of a facility with a 110,000 square foot footprint allows for scalable growth with minimal capital expenditure [33] Future Outlook - The company anticipates further growth as more international markets legalize cannabis, with a focus on facilitating exports and leveraging existing capacities [19][30] - Decibel is positioned to capture market share as new countries come online, particularly in the EU [5][30] Conclusion - Decibel Cannabis Company has a proven track record in Canada and is strategically positioned for international growth, leveraging its experience and regulatory compliance to capitalize on emerging markets [19][34]

Group 1 - Altria is recognized as a top stock for investors seeking high yield while protecting capital, particularly due to its focus on the U.S. market since its 2008 spinoff from Philip Morris International [1] - The company is transitioning from traditional cigarettes to smoke-free products, including vapes and nicotine pouches, indicating a strategic pivot in its product offerings [1] - Altria's stock has shown improved price performance, earning upgrades in its Relative Strength Rating, reflecting positive market sentiment [3] Group 2 - Altria's stock offers a dividend yield of 7.1%, positioning it as a competitive option among high-yield stocks [3] - The company has successfully mitigated tariff risks associated with its products, enhancing its market stability [3] - Altria has joined an elite group of stocks with Relative Strength Ratings over 90, showcasing its strong market performance [3]

Core Points - InHouse™ has launched its second annual Help on the Homefront campaign to support veterans with housing costs and home improvements [1][4] - The campaign runs from October 1 to November 30, 2025, offering qualifying veterans a chance to win $5,000 to alleviate housing financial burdens [2] - One winner will be selected from each of four MariMed retail markets: Maryland, Massachusetts, Delaware, and Illinois [2] Company Overview - InHouse is a value-priced cannabis brand under MariMed Inc., offering a variety of high-quality products including flower, vapes, and gummies [5] - MariMed Inc. is recognized as a leading multi-state cannabis operator, known for its innovative cultivation, production, and retail facilities [6] - The company has a portfolio of award-winning cannabis brands, including InHouse, and is committed to excellence and growth in the cannabis industry [6]

Core Points - InHouse™ has launched its second annual Help on the Homefront campaign to support veterans with housing costs and home improvements, running from October 1 to November 30, 2025 [1][2] - The campaign aims to raise awareness about veteran housing challenges and homelessness, with one veteran from each of four states (Maryland, Massachusetts, Delaware, and Illinois) eligible to win $5,000 [1][2] - Veterans aged 21 and over can enter the contest either in-store at MariMed's Thrive dispensaries or online, with no purchase necessary [3] Company Overview - InHouse is a cannabis brand under MariMed Inc., offering a range of high-quality cannabis products including flower, vapes, and gummies [5] - MariMed Inc. is recognized as a leading multi-state cannabis operator, known for its innovative cultivation, production, and retail facilities, and has a portfolio of award-winning cannabis brands [6]

Core Insights - Tilray Brands (NASDAQ: TLRY) has experienced a significant stock price increase of nearly 200%, rising from $0.42 in early July to $1.24, primarily due to potential reclassification of cannabis by the Trump administration from Schedule I to Schedule III [2][15] - The company is focusing on product differentiation and expanding its operations in Europe, including launching new EU-GMP certified medical cannabis strains in Germany [3] - Investors are questioning whether TLRY stock remains a compelling investment at its current price, with significant upside potential linked to the prospective reclassification of marijuana [4][16] Financial Performance - Tilray's revenues have grown at an average rate of 9.9% over the last three years, with a 4.1% increase from $789 million to $821 million in the past 12 months [12] - The latest quarterly revenues decreased by 2.3% to $225 million from $230 million a year prior [12] - The company reported an operating income of -$108 million, resulting in an operating margin of -13.1% and a cash flow margin of -11.5%, generating nearly -$95 million in operating cash flow [12] - TLRY's net income for the corresponding period was approximately -$2.2 billion, indicating a net margin of around -266.3% [12] Debt and Financial Stability - TLRY's debt stood at $329 million at the end of the most recent quarter, with a current market cap of $1.2 billion, resulting in a debt-to-equity ratio of 26.7% [13] - The company's cash (including cash equivalents) constitutes $256 million of $2.1 billion in total assets, leading to a cash-to-assets ratio of 12.4% [13] Stock Performance - TLRY stock has plummeted 97.6% from a peak of $63.91 on February 10, 2021, to $1.52 on June 23, 2023, compared to a peak-to-trough decline of 25.4% for the S&P 500 [14] - The stock has not yet rebounded to its pre-crisis peak, with the highest value since then being $3.31 on September 11, 2023, and currently trading at $1.24 [14] - TLRY stock dropped 88.4% from a high of $21.36 on January 15, 2020, to $2.47 on March 18, 2020, versus a peak-to-trough decline of 33.9% for the S&P 500 [14] Market Position and Strategy - Tilray Brands engages in the research, cultivation, production, marketing, and distribution of medical cannabis products across various segments, including GMP-certified flowers, oils, vapes, edibles, and topicals [7] - The company is enhancing its business operations by concentrating on product differentiation and developing new products for its premium segment [3]